Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy male and female infants aged 9 - 12 months will be recruited from Vellore, India and Dhaka, Bangladesh.~All subjects must satisfy the following criteria at study entry:~1. Male or female infants aged 9 - 12 months whose parents or primary caretaker have given the written informed consent prior to study entry~2. Will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection).~3. Healthy subjects as determined by:~   * Medical history~  * Physical examination~  * Clinical judgment of the investigator~Exclusion Criteria:~1. Parents or primary caregiver are unwilling or unable to give written informed consent to participate in the study~2. Ongoing serious chronic disease~3. Immunocompromising condition or therapy~4. Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours~5. Intake of any anti-diarrheal medicine in the past week~6. Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject~7. Receipt of antibiotics in the past 2 weeks~8. Receipt of live or killed enteric vaccine in the last 4 weeks~9. Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment~10. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months~11. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months~12. Receipt of killed oral cholera vaccine~13. Have previously received a dose of a measles-containing vaccine (MCV)~14. Have previously presented with a disease potentially related to measles~15. Receipt of blood, blood products or a parenteral immunoglobulin preparation in the previous 3 months~16. History of anaphylaxis, any serious vaccine reaction, allergy to eggs, egg products or to any measles vaccine component~17. any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).